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HAEMATOPOIETIC STEM CELL 
TRANS-PLANTATION (HSCT) 
DEFINITION 
Haematopoietic Stem Cell 
Trans-plantation is a medical procedure 
in the field of haematology and 
oncology that involves transplantation 
of haematopoietic stem cells (HSC).  It 
is most often performed for people 
with diseases of the blood or bone 
narrow or certain types of cancers. 
PRINCIPLES 
Most recipients of HSCT are 
leukaemia patients or others who 
would benefit from treatment with high 
doses of chemotherapy or total body 
irradiation (TBI).  Other beneficiaries of 
HSC include Paediatric cases that 
require bone marrow transplant; 
cases in which the patient has an 
inborn defect such as severe 
combined immunodeficiency or 
congenital neutropenia and was born 
with defective stem cells.  Children or 
adult with aplastic anaemia have lost 
their stem cells after birth and may not 
require such high doses of 
chemotherapy and irradiation prior to 
transplant.  In this case there is 
greater need for immunosuppressive 
agents.  Other conditions that bone 
marrow transplants are considered 
include thalassemia major, sickle cell 
disease, Myelodysplastic syndrome, 
lymphoma and multiple myeloma.  
More recently nonmyeloablative, or so 
called “mini transplant” procedures 
have been developed which do not 
require such large doses of 
chemotherapy and radiation.  This has 
allowed HSCT to be conducted in 
older patients without the need for 
hospitalization. 
STEM CELL COLLECTION 
Types of Donors 
There are two major types of 
bone marrow transplantation namely; 
Autologous and Allogenic transplantations. 
Autologous: Bone marrow transplantation 
involves isolation of HSC from a 
patient suffering from a blood cancer 
usually; freezing of the isolated stem 
cells; storage of the frozen stem cells; 
medical treatment of the patient that 
usually results in destruction of the 
remaining stem cells in the body; and 
then return of the stored stem cells 
back to the body.  Autologous 
transplants have the advantage of a 
lower risk of graft rejection and Graft 
Versus Host Disease. 
Allogeneic: Allogenic bone marrow 
transplantation involves two people, 
one is the (normal) donor and one is 
the (patient) recipient.  Allogeneic 
HSC donors must have a tissue (HLA) 
type that matches the recipient and in 
addition, the recipient requires immuno 
suppressive medication.  Allogeneic 
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transplant donors may be related 
(usually a sibling) or unrelated volunteers. 
Donor selection 
A major limitation of allogeneic 
bone marrow transplantation is a 
shortage of donors.  To avoid 
rejection of the transplanted stem 
cells or severe Graft Vs Host Disease 
(GVHD), the donor should have the 
same human leucocyte antigens 
(HLA) as the recipient.  About 25 to 30 
percent of potential HSCT recipient 
have an HLA – identical sibling.  For 
other recipients, registries whilst 
available, of volunteer unrelated 
donors can be quickly searched in 
order to find a potential HLA match.  If 
an exact match cannot be found, a 
partially matched donor can be used.  
However, the use of mismatched 
donors may increase the risk of graft 
rejection or severe graft – versus – 
host disease. 
A compatible donor is found by 
doing additional HLA – testing from 
the blood of potential donors.  The 
HLA genes fall into two categories 
(type I and type II).  In general, 
mismatches of the type I genes (i.e. 
HLA – A, HLA – B or HLA – C) 
increase the risk of graft rejection.  A 
mismatch of an HLA type II gene (i.e. 
HLA – DR, HLA – ADOBI) increases 
the risk of GVHD.  In addition a 
genetic mismatch as small as a single 
DNA base pair is significant.  So 
perfect matches require knowledge of 
the exact DNA sequence of these 
genes for both donor and recipient.  
Leading transplant centres currently 
perform testing for all five of these 
HLA genes before declaring that a 
donor and recipient are HLA – 
identical. 
 
Sources of HSC 
In the case of bone marrow 
transplant, the HSC are moved from 
a large bone of the donor, typically the 
pelvis, through a large needle that 
reaches the centre of the bone.  The 
technique is referred to as a bone 
marrow harvest and is performed 
under general anaesthesia because 
hundreds of insertions of the needle 
may be required to obtained sufficient 
material. 
Peripheral blood stem cells – are 
now the most common source of stem 
cells for HSCT.  They are collected 
from the blood through a process 
known as apheresis – the donor’s 
blood is withdrawn through a sterile 
needle in one arm and passed 
through a machine that removes white 
blood cells, the red blood cells are 
returned to the donor.  The peripheral 
stem cell yield is boosted with daily 
subcutaneous injections of filgrastim. 
Umbilical cord blood – is obtained 
when a mother donates her infant’s 
umbilical cord and placenta after birth.  
Cord blood has a higher concentration 
of HSC than is normally found in adult 
blood.  However, the small quantity of 
blood obtained from the umbilical cord 
(typically about 50ml) makes it more 
suitable for transplantation into small 
children than in adults.  Newer 
techniques using ex-vivo expansion of 
cord blood units or the use of two cord 
blood units from different donors are 
being explored to allow cord blood 
transplant to be used in adults. 
Storage of HSC 
Unlike other organs, bone 
marrow cells can be frozen for 
prolonged time periods (cryopreserved/ 
without damaging too many cells).  
This is necessary for autologuous 
HSC because the cells must be 
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harvested months in advance of the 
transplant treatment.  In the case of 
allogeneic transplants, HSC are 
preferred in order to avoid cell loss 
that might occur during the freezing 
and, thawing process.  Allogeneic 
cord blood is stored frozen at a cord 
blood bank because it is only 
obtainable at the time of childbirth.  To 
cryopreserve HSC, a preservative – 
DMSO must be added and the cells 
must be cooled very slowly in a 
control rate freezer to prevent osmotic 
cellular injury during ice crystal 
formation.  HSC may be stored for 
years in a cryofreezer which typically 
utilizes liquid nitrogen because it is 
non-toxic and it is very cold (boiling 
point – 196ºC). 
Conditioning Regimens 
Ablation of the diseased 
immune system is the goal of the 
conditioning regimen.  It is a 
preparative regimen with the use of 
chemotherapy or irradiation.  The 
purpose is to help eradicate the 
patient’s diseases prior to the infusion 
of HSC and to suppress immune 
reactions.  Chemotherapy drugs and 
radiation both damage DNA in the cell 
nucleus which kills rapidly dividing 
cells by triggering a self-destructive 
mechanism called apoptosis.  Bone 
marrow cells divide frequently and are 
particularly sensitive in this treatment.  
The bone marrow can be ablated at 
doses that cause minimal injury to 
other tissues.  In allogeneic transplant, 
a combination of cyclophosphamide 
with busulfan or total body irradiation 
is commonly employed.  This treatment 
also has immunosuppressive effects 
which prevents rejection of the HSC 
by the recipient immune system.  
Autologous transplants may also use 
this conditioning regimens. 
Non-Myeloablative allogeneic HSCT 
is a newer treatment approach which 
uses lower doses of chemotherapy and 
irradiation which are too low to 
eradicate all of the bone marrow cells 
of a recipient.  Instead non-myeloablative 
transplant rely on the graft versus 
tumour effect for their benefit.  They 
do require high doses of immunosuppressive 
agents in the early stage of treatment.  
This leads to a state of mixed 
chimerism early after transplant where 
both recipient and donor HSC coexist 
in the bone marrow space, decreasing 
doses of immunosuppressive therapy 
than allow donor T – cells to eradicate 
the remaining recipient HSC and to 
induce GVHD and the graft versus 
tumour effect. 
Non – myeloablastive (or “min”) 
allogeneic transplant, because of their 
gentler conditioning regimens, are 
associated with a lower risk of 
transplant – related mortality and 
therefore allow patient who are 
considered too high risk for 
conventional allogeneic HSCT 
(because of age or other 
comorbidities) to undergo potentially 
curative therapy for their disease. 
TRANSPLANTATION AND 
ENGRAFTMENT 
HSC are infused into the blood 
stream of the recipient through an 
intravenous (i.v) catheter.  Like any 
other i.v. fluid the HSC briefly circulate 
in the blood stream and then home 
into the bone marrow spaces where 
they grow and start to produce blood 
cells.  After several weeks of growth in 
the bone marrow, expansion of HSC 
and their progeny is sufficient to 
normalize the blood cell counts and 
alleviate the need for red blood cells 
and platelets transfusion. 
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Side effects and complications 
Bone marrow transplantation is 
associated with a fairly high mortality 
(10% or higher), which limits its use to 
conditions that are themselves 
essentially life threatening.  Major 
causes of complications are sepsis, 
graft-versus host disease and veno-
occlusive disease. 
Infection 
Bone marrow transplantation 
usually requires that the recipients 
own bone marrow is destroyed 
(myeloablation).  Prior to “engraftment”, 
patients may go for several weeks 
without appreciable numbers of white 
blood cells to help fight infection.  This 
puts a patient at risk of infections, 
sepsis and septic shock despite prophylactic 
antibiotics. The immunosuppressive agent 
employed in allogeneic transplant for 
the prevention or treatment of GVHD 
further increase the risk of opportunistic 
infection.  Immunosuppressive drugs are 
given for a period of 6 months after a 
transplantation or much longer if 
required for the treatment of GVHD.  
Transplant patients lose their acquired 
immunity, for example immunity to 
childhood diseases such as measles 
or polio.  For this reasons transplant 
patient must be revaccinated with 
childhood vaccines once they are off 
immuno-suppressive medications. 
GRAFT VERSUS HOST DISEASE 
GVHD is an inflammatory 
disease that is unique to allogeneic 
transplantation.  It is an attack of the 
“new” bone marrow’s immune cells 
against the recipient’s tissues.  This 
can occur even if the donor and 
recipient are HLA – identical because 
the immune system can still recognise 
other differences between their tissues.  
It is aptly named graft versus host 
disease because bone marrow 
transplantation is the only transplant 
procedure in which trans-planted cells 
must accept the body rather than the 
body accepting the new cells.  Acute 
GVHD typically occurs in the first 3 
months after transplantation and may 
involve the skin, intestine or the liver. 
Corticosteroids such as prednisolone 
are a standard treatment.  Chronic 
GVHD may also develop after 
allogeneic transplant and is the major 
source of late complications. In 
addition to inflammation, chronic 
GVHD may lead to the development 
of fibrosis or scar tissue, similar to 
scleroderma or other autoimmune 
disease and may cause functional 
disability and the need for prolonged 
immunosuppressive therapy. 
Graft versus tumour effect 
The beneficial aspect of Graft 
versus Host is known as “graft versus 
tumour” or “graft versus leukaemia”.  
For example leukaemia patient with 
chronic GVHD after an allogeneic 
transplant have lower risk of 
leukaemia relapse.  This is due to 
therapeutic immune reaction of the 
grafted donor lymphocytes against the 
disease bone marrow of the recipient.  
This lower rate of relapse accounts for 
the increased success rate of 
allogeneic transplant compared to 
transplant from identical twins, and 
indicates that allogeneic HSCT is a 
form of immunotherapy.  Graft vs 
tumour is also the major mechanism 
of benefit of non-myeloablative 
transplant which do not employ high 
dose chemotherapy or radiation. 
CONDITIONS TREATED WITH BONE 
MARROW TRANSPLANT 
Acquired 
1. Acute lymphocytic leukaemia 
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2. Acute myelogenous leukaemia 
3. Aplastic anaemia 
4. Chronic myelogenous leukaemia 
– accelerated phase or blast 
crises 
5. Hodgkin’s disease 
6. Multiple myeloma 
7. Myelodysplasia 
8. Non – Hodgkin’s lymphoma 
9. Paroxysmal nocturnal haemoglobinuria 
(PNH) – severe aplasia 
10. Radiation poisoning. 
Congenital 
1. Adrenoleukodystrophy 
2. Hurler syndrome 
3. Kostmann syndrome 
4. Drabbe disease 
5. Metachromatic leukodystrophy 
6. Hemophagocytic 
lymphohistocytosis (HLH) 
7. Wiskot – Aldrich syndrome 
8. Some inborn errors of metabolism. 
SUMMARY AND CONCLUSION 
Transplantation of allogeneic 
haema-topoietic stem cells is an 
established treatment for some 
relatively rare malignant blood diseases, 
congenital or acquired diseases with 
severe bone marrow failure, and 
certain metabolic diseases.  The best 
documentation is found for treatment 
using bone marrow or stem cells 
mobilized to peripheral blood from 
HLA – compatible donors both related 
and unrelated.  Since 1990, cord 
blood from related or unrelated donors 
has been used as an alternative to 
stem cells from bone marrow or blood. 
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